Acknowledgment and Consent for Disclosure of
Section 712(c)(2)(B) of the Federal Food, Drug, and Cosmetic Act
and 18 U.S.C. §208
Particular Matter Waiver

Name: Thomas Kosten, M.D.

Committee: Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees

Meeting Date(s): May 5-6, 2008

I acknowledge that contingent upon public disclosure of the following financial interests submitted on my FDA Form 3410 and related to the agenda item: (1) New Drug Application (NDA) 22-272, oxycodone hydrochloride controlled-release tablets (trade name OxyContin), a purportedly less abusable formulation sponsored by Purdue Pharma L.P., for the proposed indication of management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time; and (2) supplemental New Drug Application (sNDA) 21-947/s-005, fentanyl buccal tablet (tradename Fentora), Cephalon, Inc., for the proposed indication of breakthrough pain in opioid tolerant non-cancer patients with chronic pain, I am eligible to receive a particular matter waiver under Section 712(c)(2)(B) and 18 U.S.C. §208.

Type of Interest	**Involvement**	**Magnitude**
Stock	Competitor	Valued from $25,001 to $50,000

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of the interest, the waivers are not valid.

/S/ 3/31/08

Signature Date